Press release
Candidiasis Therapeutics Market Analysis With Key Players, Applications, Trends And Forecast To 2033
Candidiasis Therapeutics Market
The Business Research Company offers in-depth market insights through Candidiasis Therapeutics Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in 2023 to $3.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs..
The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance.. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives..
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp
Market Segmentation:
The candidiasis therapeutics market covered in this report is segmented -
1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode of Administration: Injectable, Oral, Other Mode of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Major Driver - Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Market
The growing incidence of fungal infections is expected to propel the growth of the candidiasis therapeutics market going forward. Fungal infections are illnesses caused by various fungi that can affect the skin, mucous membranes, and internal organs in humans. The rising number of individuals with compromised immune systems and individuals with fungal infections increases the susceptibility to candidiasis, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs that target the underlying fungal pathogens, relieve symptoms, prevent complications, promote patient recovery, reduce the spread of Candida infections within healthcare facilities, and contribute to better patient outcomes. For instance, in July 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, fungal infection-related hospitalizations reached a total of 59,212 by 2021, with the rate of these hospitalizations increasing from 25.0 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, with an average annual increase of 8.5%. Moreover, the fungal hospitalizations with the highest death rates among COVID-19 patients were linked to aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%), and unspecified mycoses (59.0%). Therefore, the growing incidence of fungal infections will drive the growth of the candidiasis therapeutics market.
Competitive Landscape:
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
Top Trend - Innovative Drugs Transforming The Candidiasis Treatment
Major companies operating in the candidiasis therapeutics market are developing innovative drugs such as BREXAFEMME (ibrexafungerp tablets) to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) is an oral, non-azole medication for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a US-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. BREXAFEMME works by blocking the growth of Candida albicans, the fungus that causes VVC. Moreover, it is a safe and effective treatment option for vulvovaginal candidiasis (VVC). It is also available only by prescription, with a recommended dose of one 150-mg capsule taken orally once daily for one day.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Candidiasis Therapeutics Market Characteristics
3. Candidiasis Therapeutics Market Trends And Strategies
4. Candidiasis Therapeutics Market - Macro Economic Scenario
5. Candidiasis Therapeutics Market Size And Growth
…..
27. Candidiasis Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Candidiasis Therapeutics Market Analysis With Key Players, Applications, Trends And Forecast To 2033 here
News-ID: 3435055 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Candidiasis
Candidiasis Market New Product Development & Latest Trends
Introduction
Candidiasis, a fungal infection caused by Candida species, represents a major healthcare challenge worldwide. While Candida albicans is the most common pathogen, emerging strains such as Candida auris are raising global concerns due to their high resistance to antifungal drugs. Candidiasis can affect the mouth (oral thrush), genital areas, bloodstream, and internal organs, with systemic infections often proving life-threatening, especially in immunocompromised patients.
The growing prevalence of hospital-acquired infections (HAIs), rising…
Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Mar …
The Candidiasis Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Candidiasis Therapeutics Market Size and Projected Growth Rate?
Recent years have seen consistent growth in the size of the market for candidiasis therapeutics. This is predicted to further expand from $3.19 billion…
Acute Vulvovaginal Candidiasis Market Beyond Douching: New Treatment Options Dri …
Acute Vulvovaginal Candidiasis Market worth $ 485.54 Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, , Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast…
Recurrent Vulvovaginal Candidiasis Market - Defeating Recurrent Vulvovaginal Can …
Newark, New Castle, USA: The "Recurrent Vulvovaginal Candidiasis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Recurrent Vulvovaginal Candidiasis Market: https://www.growthplusreports.com/report/recurrent-vulvovaginal-candidiasis-market/8832
This latest report researches the industry structure,…
Candidiasis Epidemiology Insights to 2025
Publisher " Candidiasis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Candidiasis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Candidiasis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with…
Candidiasis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Candidiasis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.
Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin…
